{"id":389895,"date":"2022-02-11T00:00:00","date_gmt":"2022-02-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreid0003-2016-biopharma-hepatitis-c-virus-access-and-reimbursement-eu5-2016\/"},"modified":"2026-03-31T10:40:50","modified_gmt":"2026-03-31T10:40:50","slug":"acreid0003-2016-biopharma-hepatitis-c-virus-access-and-reimbursement-eu5-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreid0003-2016-biopharma-hepatitis-c-virus-access-and-reimbursement-eu5-2016\/","title":{"rendered":"Hepatitis C Virus | Access and Reimbursement | EU5 | 2016"},"content":{"rendered":"<p>Chronic infection with hepatitis C virus (HCV) is a leading cause of advanced liver disease and hepatocellular carcinoma and a common indication for liver transplantation. The 2013-2015 EMA approvals of Gilead\u2019s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir\/ledipasvir), combined with Bristol-Myers Squibb\u2019s Daklinza (daclatasvir) and AbbVie\u2019s Viekirax + Exviera (ombitasvir\/paritaprevir\/ritonavir + dasabuvir), have ushered in the era of interferon (IFN)-free direct-acting antiviral (DAA) therapy for chronic HCV infection and completely reshaped the HCV therapeutic market. The EMA\u2019s recent authorization of Gilead\u2019s Epclusa (sofosbuvir\/velpatasvir) provides the first FDC approved for all HCV genotypes. Hepatitis C Virus | Access &#038; Reimbursement | EU5 examines the market access factors that influence the success of IFN-free DAA therapies in the EU5 markets. The series is based on primary research with EU5 gastroenterologists and hepatologists, as well as country-specific payers. This research explores how payers and physicians interact and how reimbursement decisions influence the prescribing and uptake of specific therapies at the brand level.<\/p>\n","protected":false},"template":"","class_list":["post-389895","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389895\/revisions"}],"predecessor-version":[{"id":576273,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389895\/revisions\/576273"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}